Telehealth Prior Authorization Fraud: What the Insurer Was Told

Telehealth prior authorization fraud uses false statements about a patient’s diagnosis, treatment or medical history to obtain insurance coverage for a prescription. The clinical team, authorization team and pharmacy can hold different accounts of the same prescription. If you work in prescribing, authorization or pharmacy operations, you may know exactly where the story changed to get the drug paid for.

The Prescription Can Be the Product

A remote consultation can produce a prescription that earns money elsewhere in the business. The patient’s subscription, the clinician’s compensation and the pharmacy’s reimbursement each pay for a different part of the transaction.

In its telemedicine Special Fraud Alert, the HHS Office of Inspector General described companies paying practitioners to order unnecessary products for people they barely assessed. The companies then sold the orders to businesses that billed federal healthcare programs. Payments to practitioners sometimes carried the labels review, audit, consult or assessment. What the business bought was the order.

The consultation itself may never generate an insurance claim. A federal indictment describing an order-selling network alleged that the companies avoided charging patients or Medicare for the purported consultation while selling the resulting orders.

For prescriptions, pharmacy benefit managers process claims and audit participating pharmacies. The clinical decision, the authorization request and the pharmacy claim therefore leave records with different participants. Understanding that separation is how we connect the employee who knows what happened during care to the statement that obtained payment.

What Are Some Examples of Prescription Fraud?

False prior authorization for a telehealth prescription can invent a treatment history that makes the drug eligible for payment. Done’s criminal trial shows how the insurer’s account can depart from the care.

In its account of evidence from the Done criminal trial, the Justice Department described false prior authorization requests claiming that Done followed DSM-5 diagnostic criteria, used urine drug screens, and had already tried non-stimulant drugs without success. The department reported that Medicare, Medicaid and commercial insurers paid approximately $12.3 million as a result.

Each statement described something that could be compared with the patient’s actual care. Was there a drug screen? Which non-stimulant had been tried? Where was the assessment supporting the diagnosis? An employee who knows how those answers reached the insurer can connect the clinical record to the payment request.

The department also explained the business reason for the false submissions: members needed insurance to pay for Adderall at pharmacies so they would keep paying Done’s monthly subscription fees. The insurer’s payment supported the platform’s recurring revenue. The false treatment histories shifted the cost to taxpayers and other insurance payers.

Pharmacy Assurances After Prescriptions Were Blocked

Pharmacy assurances can concern the company’s prescribing practices as well as the individual prescription. In the same account of the criminal trial, the Justice Department described national pharmacy chains blocking Done prescriptions over safety concerns. Done’s executives falsely claimed the company had compliance measures in place to keep pharmacies dispensing.

The department also reported that internal documents showed the founder created Mindful Mental Wellness specifically to bypass pharmacy blocks. That is a concrete pattern for an insider who sees a telehealth company sending prescriptions under a new name after pharmacies block them.

The Done indictment alleged that false representations about prescribing practices and policies interfered with pharmacies’ review of the prescriptions and caused them to submit false claims. It also alleged the creation of false patient records.

A pharmacy inquiry can therefore expose more than a missing attachment. The question, the response, the clinical record and the identity used to transmit the prescription can show how the company answered scrutiny. The employee handling the inquiry may see a contradiction that the person processing the claim never sees.

The Operating Rules Behind the Authorization

The Justice Department’s account of the Done criminal trial connects prescribing pressure and automatic refills to reduced follow-up. Those internal practices can be compared with the safeguards the company claimed to pharmacies.

The trial account described repeated warnings from clinical leaders and continued prescribing despite those warnings. Those communications belong beside the authorization and pharmacy assurances. A statement that the company followed a clinical safeguard has a different meaning when the people responsible for care had already told management the safeguard was missing.

One Prescription, Different Accounts

We examine what each account says about the same patient and prescription. The original authorization request and the insurer’s response show what the company submitted to secure coverage. A revised submission after a denial adds another version to compare: who supplied the new information, and whether it appeared in the clinical record before the denial.

On the dispensing side, the pharmacy’s question and the company’s answer identify the assurance the pharmacy received. Prescription transmissions and reimbursement connect that assurance to what followed. The point is the particular statement and its consequence: what the recipient needed to know, what it was told, and what it paid for.

HealthRight and the Referral Source the Payer Never Saw

Concealing a prescription’s source can hide the commercial arrangement that produced it. The Sixth Circuit’s opinion in the criminal case involving Synergy Pharmacy Services and HealthRight describes the chain in unusually concrete terms.

The opinion describes Synergy concealing HealthRight’s involvement, including removing its name from prescriptions submitted for payment. Express Scripts required prescriptions to arise from a valid doctor-patient relationship involving an interaction between them. The missing referral name helped hide how those prescriptions had actually been generated.

The Audit Response Can Carry Another False Story

An audit response can conceal the same conduct that the original claim concealed. The Synergy criminal-case opinion describes altered statements, credit-card receipts and software notes designed to make it appear that patients had paid copays. An employee responsible for audit responses testified that management knew about the falsifications.

The opinion also describes an audit call in which the pharmacist-in-charge told CVS Caremark that Synergy used no outside marketing, spoke with every patient and collected copays before mailing medication. Those assurances concerned the business relationships and patient contacts behind the claims.

Real drugs reached patients, but the court’s payment analysis focused on the facts concealed to obtain insurers’ money. It explained that Synergy generated prescriptions the pharmacy benefit managers would not have paid for had they known their source and how they were produced. Delivery did not answer what induced the payment.

That is why we put an audit team’s original records beside its submitted answers. The response can show who knew the payer’s requirements and what the company changed when asked to account for its claims.

What Evidence Is Needed to Prove Fraud?

For prior authorization fraud, the useful evidence connects the clinical record with the statement sent to the insurer or pharmacy and the resulting claim or payment. We work with you to identify which records carry the case.

The authorization and payment can also be compared with what happened to the medication. A whistleblower complaint against Vici Marketing alleged that Z-Stat kept both the medication and the money from Tricare, Medicare or Medicaid when it obtained authorization without confirming the patient’s address.

A company’s internal analysis can explain the connection between its payments and claims. Plausible Cause: Connecting the FCA and AKS in the Context of Health Care Fraud, published in Rutgers University Law Review in 2024, makes that point:

That is the value an authorization specialist, clinician or pharmacy employee can bring: knowledge of how the business’s records fit together and what its own analyses say about them.

Medicare Telehealth Extension Versus DEA Extension in 2026

Medicare telehealth coverage and permission to prescribe controlled substances run on separate rules and dates. The Centers for Medicare & Medicaid Services’ February 2026 telehealth FAQ permits beneficiaries to receive Medicare telehealth services anywhere in the United States and territories through December 31, 2027. The Drug Enforcement Administration’s fourth temporary extension extends qualifying remote controlled-substance prescribing without a prior in-person evaluation through December 31, 2026.

A telehealth prescription still needs a legitimate medical purpose despite the waiver of the prior in-person evaluation. The temporary rule retains that requirement and the usual course of professional practice.

For a telehealth controlled-substance prescription to a patient in another state, the temporary rule requires the appropriate DEA registration or exemption. Federal permission does not supply state authorization. We compare patient location, practitioner authority and the prescription date with the assurance given to the pharmacy.

For telehealth buprenorphine audio-only prescriptions, the fourth extension describes a qualifying opioid-use-disorder treatment route and gives December 31, 2025 as the effective date of the separate buprenorphine telemedicine rule. These are distinct prescribing authorities with different requirements.

As of the December 2025 extension, DEA’s special registration rule was still proposed, not final. A general assurance that telehealth had been extended cannot answer which authority covered the prescription.

What the Billing Pattern Leaves Out

The Inspector General’s telemedicine alert identifies recruited patients, insufficient clinical contact, volume-based pay, a narrow product offering and missing follow-up as suspect characteristics. It also identifies companies serving only federal-program beneficiaries and companies claiming to exclude them while billing federal programs. These patterns help explain where to examine the order, the payment and the representations.

The Inspector General’s claims-screening report calls for further investigation of flagged providers. An insider may know why an answer changed after a denial, who removed a referral source, or which compliance assurance contradicted the company’s own warnings. That knowledge supplies the part a billing pattern leaves out.

When You Know Why the Answer Changed

If you know the treatment history behind a false authorization or the reality behind a pharmacy assurance, speak with our whistleblower experts about that prescription’s payment trail. We work with you to build the case around the statements, decisions and payments, and bring in telehealth fraud whistleblower lawyers who understand prescribing and pharmacy reimbursement. We stay beside you from that first account through the case. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.